TABLE 4.
Probability of target attainment for an unbound ceftriaxone concentration Cmin/MIC of >1 over the first 24 h of therapya
| Dose | CLCR (mL/min) | Albumin (g/L) | Probability of achieving Cmin/MIC of >1 |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.032 | 0.064 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | |||
| 1 g q24h | 40 | 20 | 1 | 1 | 1 | 0.98 | 0.86 | 0.61 | 0.33 | 0.11 | 0 |
| 40 | 30 | 1 | 1 | 1 | 1 | 0.91 | 0.70 | 0.39 | 0.12 | 0 | |
| 40 | 40 | 1 | 1 | 1 | 1 | 0.94 | 0.77 | 0.42 | 0.12 | 0 | |
| 100 | 20 | 1 | 1 | 0.97 | 0.88 | 0.67 | 0.32 | 0.10 | 0.03 | 0 | |
| 100 | 30 | 1 | 1 | 1 | 0.94 | 0.79 | 0.50 | 0.13 | 0.03 | 0 | |
| 100 | 40 | 1 | 1 | 1 | 0.98 | 0.86 | 0.58 | 0.17 | 0.03 | 0 | |
| 160 | 20 | 0.99 | 0.97 | 0.9 | 0.73 | 0.36 | 0.13 | 0.07 | 0.02 | 0 | |
| 160 | 30 | 1 | 0.99 | 0.96 | 0.84 | 0.59 | 0.20 | 0.08 | 0.02 | 0 | |
| 160 | 40 | 1 | 1 | 0.98 | 0.91 | 0.72 | 0.31 | 0.09 | 0.02 | 0 | |
| 2 g q24h | 40 | 20 | 1 | 1 | 1 | 1 | 0.95 | 0.82 | 0.53 | 0.28 | 0.10 |
| 40 | 30 | 1 | 1 | 1 | 1 | 0.99 | 0.88 | 0.65 | 0.32 | 0.10 | |
| 40 | 40 | 1 | 1 | 1 | 1 | 1 | 0.92 | 0.72 | 0.35 | 0.10 | |
| 100 | 20 | 1 | 1 | 1 | 0.95 | 0.86 | 0.60 | 0.25 | 0.08 | 0.03 | |
| 100 | 30 | 1 | 1 | 1 | 1 | 0.91 | 0.75 | 0.37 | 0.10 | 0.03 | |
| 100 | 40 | 1 | 1 | 1 | 1 | 0.96 | 0.81 | 0.50 | 0.12 | 0.03 | |
| 160 | 20 | 1 | 0.99 | 0.96 | 0.88 | 0.65 | 0.27 | 0.11 | 0.06 | 0.02 | |
| 160 | 30 | 1 | 1 | 1 | 0.95 | 0.81 | 0.49 | 0.14 | 0.06 | 0.02 | |
| 160 | 40 | 1 | 1 | 1 | 0.98 | 0.88 | 0.65 | 0.21 | 0.07 | 0.02 | |
| 1 g q12h | 40 | 20 | 1 | 1 | 1 | 1 | 0.99 | 0.94 | 0.76 | 0.40 | 0.07 |
| 40 | 30 | 1 | 1 | 1 | 1 | 0.99 | 0.97 | 0.78 | 0.39 | 0.05 | |
| 40 | 40 | 1 | 1 | 1 | 1 | 1 | 0.98 | 0.79 | 0.35 | 0.03 | |
| 100 | 20 | 1 | 1 | 1 | 1 | 0.97 | 0.86 | 0.62 | 0.15 | 0.01 | |
| 100 | 30 | 1 | 1 | 1 | 1 | 0.99 | 0.88 | 0.68 | 0.17 | 0.01 | |
| 100 | 40 | 1 | 1 | 1 | 1 | 1 | 0.93 | 0.71 | 0.15 | 0.01 | |
| 160 | 20 | 1 | 1 | 1 | 0.99 | 0.92 | 0.76 | 0.33 | 0.07 | 0.01 | |
| 160 | 30 | 1 | 1 | 1 | 1 | 0.96 | 0.80 | 0.46 | 0.07 | 0.01 | |
| 160 | 40 | 1 | 1 | 1 | 1 | 0.97 | 0.83 | 0.52 | 0.07 | 0.01 | |
| 2 g q12h | 40 | 20 | 1 | 1 | 1 | 1 | 1 | 0.99 | 0.90 | 0.73 | 0.35 |
| 40 | 30 | 1 | 1 | 1 | 1 | 1 | 0.99 | 0.94 | 0.75 | 0.36 | |
| 40 | 40 | 1 | 1 | 1 | 1 | 1 | 1 | 0.97 | 0.76 | 0.34 | |
| 100 | 20 | 1 | 1 | 1 | 1 | 0.99 | 0.95 | 0.82 | 0.52 | 0.13 | |
| 100 | 30 | 1 | 1 | 1 | 1 | 0.99 | 0.98 | 0.86 | 0.61 | 0.13 | |
| 100 | 40 | 1 | 1 | 1 | 1 | 1 | 0.99 | 0.88 | 0.66 | 0.13 | |
| 160 | 20 | 1 | 1 | 1 | 1 | 0.98 | 0.91 | 0.72 | 0.24 | 0.07 | |
| 160 | 30 | 1 | 1 | 1 | 1 | 0.99 | 0.93 | 0.77 | 0.33 | 0.06 | |
| 160 | 40 | 1 | 1 | 1 | 1 | 1 | 0.97 | 0.78 | 0.33 | 0.06 | |
| 1 g q8h | 40 | 20 | 1 | 1 | 1 | 1 | 1 | 0.97 | 0.85 | 0.61 | 0.17 |
| 40 | 30 | 1 | 1 | 1 | 1 | 1 | 0.98 | 0.88 | 0.61 | 0.12 | |
| 40 | 40 | 1 | 1 | 1 | 1 | 1 | 0.99 | 0.89 | 0.55 | 0.09 | |
| 100 | 20 | 1 | 1 | 1 | 1 | 0.99 | 0.94 | 0.78 | 0.41 | 0.05 | |
| 100 | 30 | 1 | 1 | 1 | 1 | 1 | 0.96 | 0.80 | 0.41 | 0.04 | |
| 100 | 40 | 1 | 1 | 1 | 1 | 1 | 0.97 | 0.81 | 0.35 | 0.04 | |
| 160 | 20 | 1 | 1 | 1 | 1 | 0.98 | 0.88 | 0.71 | 0.17 | 0.03 | |
| 160 | 30 | 1 | 1 | 1 | 1 | 0.99 | 0.92 | 0.75 | 0.19 | 0.03 | |
| 160 | 40 | 1 | 1 | 1 | 1 | 1 | 0.95 | 0.77 | 0.19 | 0.02 | |
| 2 g q8h | 40 | 20 | 1 | 1 | 1 | 1 | 1 | 0.99 | 0.96 | 0.81 | 0.57 |
| 40 | 30 | 1 | 1 | 1 | 1 | 1 | 1 | 0.98 | 0.85 | 0.57 | |
| 40 | 40 | 1 | 1 | 1 | 1 | 1 | 1 | 0.98 | 0.86 | 0.54 | |
| 100 | 20 | 1 | 1 | 1 | 1 | 1 | 0.99 | 0.91 | 0.45 | 0.32 | |
| 100 | 30 | 1 | 1 | 1 | 1 | 1 | 0.99 | 0.94 | 0.77 | 0.34 | |
| 100 | 40 | 1 | 1 | 1 | 1 | 1 | 1 | 0.96 | 0.79 | 0.34 | |
| 160 | 20 | 1 | 1 | 1 | 1 | 0.99 | 0.96 | 0.86 | 0.63 | 0.14 | |
| 160 | 30 | 1 | 1 | 1 | 1 | 1 | 0.98 | 0.89 | 0.71 | 0.15 | |
| 160 | 40 | 1 | 1 | 1 | 1 | 1 | 0.99 | 0.92 | 0.74 | 0.16 | |
| 1-g LD + 2-g CI | 40 | 20 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.96 | 0.72 |
| 40 | 30 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.96 | 0.66 | |
| 40 | 40 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.96 | 0.52 | |
| 100 | 20 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.89 | 0.52 | |
| 100 | 30 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.88 | 0.49 | |
| 100 | 40 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.87 | 0.39 | |
| 160 | 20 | 1 | 1 | 1 | 1 | 1 | 1 | 0.98 | 0.82 | 0.26 | |
| 160 | 30 | 1 | 1 | 1 | 1 | 1 | 1 | 0.98 | 0.82 | 0.26 | |
| 160 | 40 | 1 | 1 | 1 | 1 | 1 | 1 | 0.98 | 0.82 | 0.23 | |
| 1-g LD + 4-g CI | 40 | 20 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.91 |
| 40 | 30 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.85 | |
| 40 | 40 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.73 | |
| 100 | 20 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.99 | 0.82 | |
| 100 | 30 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.99 | 0.78 | |
| 100 | 40 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.98 | 0.69 | |
| 160 | 20 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.98 | 0.78 | |
| 160 | 30 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.98 | 0.74 | |
| 160 | 40 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0.98 | 0.63 | |
a
LD, loading dose; CI, continuous infusion; CLCR, creatinine clearance; q8h, q12h, and q24h, administered every 8, 12, and 24 h, respectively.